Rare Bone Disease


Canada Approves Palovarotene treatment for FOP

On Jan 24, Ipsen announced the Canada approval of Sohonos (palovarotene). Indicated to reduce new bone formation in adults and children with FOP. Sohonos is approved for both chronic use, and for flare-ups. It is the first approval for Sohonos worldwide.

ERBF Call to Action

The CALL TO ACTION project

The European Rare Bone Forum, requested a proposal from Costello Medical to assist in a call to action to shorten the time between research and clinical care.

QoL Studies in Rare Bone Diseases: why, who & how?

Please join us on Thursday October 29, 2020 15h CET. Julia Quitmann (University Medical Center, Hamburg – Eppendorf) will be our Speaker addressing Quality of Life Studies in Rare Bone Diseases: why, who and how? This Webinar has the support of the European Calcified Tissue Society (ECTS).